Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease
Ramon L. Varcoe(Cornell University), Sahil A. Parikh(NewYork–Presbyterian Hospital), Nutte Teraphongphom(Cornell University), Jennifer Jones-McMeans(Cornell University), Steven Kum(Cornell University), Ido Weinberg(Harvard University), John H. Rundback(Holy Name Medical Center), Yazan Khatib, Jen‐Kuang Lee(Cornell University), Karine Ruster(Cornell University), Jin Wang(Cornell University), Mehdi H. Shishehbor, Raghu Kolluri(OhioHealth), Danielle Bajakian, Ehrin J. Armstrong(VA Eastern Colorado Health Care System), Prakash Krishnan(Mount Sinai Hospital), Andrew Holden(University of Auckland), Héctor M. García‐García(MedStar Washington Hospital Center), Marc P. Bonaca(University of Colorado Anschutz Medical Campus), Yan Zheng(Cornell University), D. Chris Metzger(Cornell University), Lawrence A. Garcia, Brian G. DeRubertis
Cited by 112
Related Papers
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
|New England Journal of Medicine|2015|2k
Rivaroxaban in Peripheral Artery Disease after Revascularization
|New England Journal of Medicine|2020|966
Vorapaxar in the Secondary Prevention of Atherothrombotic Events
|New England Journal of Medicine|2012|941